Skip to main
KMDA
KMDA logo

Kamada (KMDA) Stock Forecast & Price Target

Kamada (KMDA) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Kamada Ltd is projected to report revenues of $43.5 million for 2Q25, marking a 7% annual increase, with earnings per share expected to rise to $0.08 from $0.07 year-over-year. The anticipated revenue growth is attributed to an ongoing increase in sales of proprietary products in the U.S., the launch of new biosimilars in Israel, and sustained shipments of Kamrab and Varizig to Latin America under a significant three-year contract established in January 2025. This strong financial performance is further underscored by a substantial 19% revenue growth in 1Q25, primarily driven by heightened sales of proprietary products such as Glassia and Kamrab, along with royalty income.

Bears say

Kamada Ltd has faced challenges that have negatively impacted its financial performance, particularly within its Proprietary Products segment, which is the primary source of revenue. The company has reported a decline in sales for its key products, raising concerns about its ability to maintain market traction and profitability. Additionally, increased operational costs and competitive pressures in the therapeutic landscape have further strained the company’s financial outlook.

Kamada (KMDA) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kamada and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kamada (KMDA) Forecast

Analysts have given Kamada (KMDA) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Kamada (KMDA) has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kamada (KMDA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.